The Philips CPAP lawsuit has entered a critical new phase in 2026. Settlement checks are actively flowing to tens of thousands of claimants under the $1.1 billion personal injury agreement — but 623 cancer and serious-injury cases remain unresolved in federal court, no court-approved individual cancer injury settlements have been issued, and a second Class I FDA recall issued in August 2024 has opened the door for an entirely new wave of potential claimants. If you used a recalled Philips CPAP, BiPAP, or ventilator device and have not yet determined where you stand legally, this update is urgent reading.
Where the Philips CPAP Lawsuit Stands Right Now in 2026
The Philips CPAP lawsuit traces its origins to June 2021, when Philips Respironics recalled approximately 5.5 million CPAP, BiPAP, and mechanical ventilator devices in the United States — roughly 15 million units worldwide. The recall was triggered by the degradation of polyester-based polyurethane (PE-PUR) sound-abatement foam embedded in the devices. As that foam breaks down, it releases toxic black particles and carcinogenic gases directly into the breathing pathways of patients. The chemicals at issue — toluene diamine, toluene diisocyanate, and diethylene glycol — are classified as potential or known carcinogens. The FDA designated the recall as Class I, its most serious category, reserved for situations where there is a reasonable probability that use of the product will cause serious injury or death.
All litigation was consolidated into MDL 3014 in the Western District of Pennsylvania under Senior Judge Joy Flowers Conti. As of July 8, 2026, confirmed reporting from Drugwatch places the number of still-pending cases in MDL 3014 at 623, with zero court-approved individual cancer injury settlement offers having been issued. That number is the single most important data point for anyone following this mass tort in 2026: the economic-loss and medical monitoring tracks are in disbursement, but cancer claimants are still waiting.
The Two Settlement Tracks: What Has Been Paid and What Has Not
Understanding the Philips CPAP lawsuit settlement landscape requires separating two distinct compensation frameworks that were negotiated years apart and cover fundamentally different categories of harm.
The $479 Million Economic-Loss Class Action Settlement (September 2023)
In September 2023, Philips settled an economic-loss class action for $479 million. This settlement addressed device replacement costs and diminished value damages — it compensated users for the economic harm of owning a defective device. Critically, this settlement does not compensate anyone for personal physical injuries, cancers, or death. It was a property and consumer-harm settlement, not a medical injury settlement. Many device owners who registered for this track have already received payment.
The $1.1 Billion Personal Injury and Wrongful Death Settlement (April/May 2024)
In April and May of 2024, Philips reached a broader $1.1 billion personal injury and wrongful death settlement — the agreement that affects claimants with diagnosed medical conditions linked to foam exposure. The structure breaks down as follows: $1.075 billion allocated to personal injury claims using a points-based severity system, and $25 million dedicated to a medical monitoring fund. Registration for this settlement closed on January 31, 2025, and disbursement is actively underway in 2026. Estimated individual settlement values range from $100,000 to $500,000 per claim, depending on injury severity as measured by the allocation point system. Lung cancer, nasal cancer, and serious inflammatory respiratory disease represent the core personal injury categories. For a general understanding of how mass tort compensation is typically structured, an personal injury settlement calculator can help contextualize the value range of injury-based claims.
What Remains Unresolved: The 623 Live Cancer Cases
Despite disbursement being underway, the 623 cases still pending in MDL 3014 as of July 2026 represent claimants — primarily those with cancer diagnoses — who either opted out of the global resolution, whose claims were not absorbed into the settlement framework, or whose cases involve disputed eligibility. No court-approved individual cancer injury settlement offers have been made in these remaining cases. These plaintiffs are still in active federal litigation. For wrongful death claims in this category, families should understand how fatal mass tort cases are evaluated — a wrongful death calculator can illustrate the factors courts and mediators use when valuing fatal injury claims.
Key Statistics: Philips CPAP Recall and Lawsuit Data Table
| Data Point | Figure | Source / Date |
|---|---|---|
| U.S. devices recalled (June 2021) | ~5.5 million units | FDA, June 2021 |
| Worldwide devices recalled | ~15 million units | FDA, June 2021 |
| FDA recall classification | Class I (most serious) | FDA |
| Foam-related death reports to FDA (by June 2023) | 385 reported deaths | FDA MDR database, June 2023 |
| Total FDA complaints received | 105,000+ | FDA, June 2023 |
| Economic-loss class action settlement | $479 million | MDL 3014, September 2023 |
| Personal injury / wrongful death settlement | $1.1 billion ($1.075B PI + $25M monitoring) | MDL 3014, April/May 2024 |
| Settlement registration deadline | January 31, 2025 | MDL 3014 court order |
| Estimated individual PI settlement range | $100,000 – $500,000 | Points-based allocation structure |
| Pending MDL cases as of July 2026 | 623 active cases | Drugwatch, July 8, 2026 |
| Court-approved individual cancer settlements | 0 as of July 2026 | Drugwatch, July 8, 2026 |
| Second Class I recall (BiPAP A30/A40/V30) | August 4, 2024 — 8 deaths, 13 injuries | FDA, August 2024 |
| Earliest known internal foam complaints at Philips | 2008 — 13 years before recall | MDL discovery documents |
| Philips initial U.S. recall reserve | $1.3+ billion | Philips N.V. financial disclosures |
The August 2024 Second Class I Recall: A New Category of Claimants
The Philips CPAP lawsuit ecosystem expanded significantly in August 2024 when the FDA issued a second Class I recall — entirely separate from the 2021 foam degradation recall — covering Philips BiPAP A30, A40, and V30 Auto ventilators. This recall was triggered by a Ventilator Inoperative alarm failure: the alarm system that is supposed to alert users and caregivers when the device stops functioning was found to be unreliable. The FDA confirmed at least 8 deaths and 13 injuries linked to this specific defect as of the recall date. This is not a foam chemical exposure issue — it is a distinct mechanical failure that silently endangered some of the most medically vulnerable patients, those dependent on ventilator support for survival.
Patients and families affected by the 2024 ventilator recall who did not participate in the 2021 recall litigation may have entirely new, independent legal claims. The statute of limitations for defective medical device claims typically runs 2 to 4 years from the date of injury or symptom discovery, depending on state law. Anyone harmed by the 2024 alarm failure defect should treat 2026 as an active window for claim evaluation. For device-related injuries that involve potential medical malpractice overlaps — such as when a prescribing physician or hospital failed to notify a patient of a recall — a medical malpractice calculator can help estimate the potential value of combined device and provider liability claims.
What Philips Knew and When: The Internal Discovery Timeline
One of the most legally significant aspects of the Philips CPAP lawsuit is what internal discovery documents revealed about the company’s pre-recall knowledge. According to documents produced in MDL 3014, Philips received foam-related complaints and internal reports as far back as 2008 — more than a decade before the June 2021 public recall. The FDA had received over 105,000 complaints and 385 foam-related death reports by June 2023, a volume that reflects the scale of potential harm that accumulated during the years when no public warning was issued.
This timeline matters for two reasons in 2026. First, it strengthens the legal theory of willful concealment, which can support punitive damages in cases that go to individual trial — relevant to the 623 still-pending MDL cases. Second, it may affect how courts interpret the statute of limitations for late-filing claimants who argue they could not have known about the risk until the 2021 recall, or later, when internal documents became public. The legal doctrine of the discovery rule, which tolls the statute of limitations until a plaintiff knew or reasonably should have known of the injury and its cause, is directly applicable to many remaining Philips claimants.
Are You Still Eligible? Who Can File a Claim in 2026
The primary personal injury settlement registration window closed on January 31, 2025, meaning most claimants who did not engage with the settlement process by that deadline are not eligible for the $1.075 billion allocation pool. However, eligibility in 2026 is not a closed question for everyone. Several categories of potential claimants remain legally viable:
- The 623 active MDL claimants — those already in litigation whose cancer or serious injury cases remain unresolved and are proceeding through MDL 3014.
- August 2024 second recall victims — individuals or families harmed by the BiPAP A30/A40/V30 ventilator alarm failure have claims arising from a distinct and separately recalled device. Their statute of limitations clock runs from injury discovery, not from 2021.
- Late-diagnosed cancer patients — individuals who used recalled devices but did not receive a qualifying cancer diagnosis until after the registration deadline may have arguments under the discovery rule depending on their state of residence.
- Wrongful death claimants — families of individuals who died after January 2025 from cancers or injuries causally linked to device exposure may have independent wrongful death claims not covered by the settled pool.
Under the settlement’s eligibility framework, claimants needed attorney representation before April 29, 2024, or to be proceeding pro se with existing filed claims. Anyone falling outside those parameters for the 2021 foam recall claims faces significant procedural hurdles for the settled pool but may still have viable independent litigation options, particularly for second-recall injuries. State-specific statutes of limitations — ranging from 2 to 4 years depending on jurisdiction — govern whether new filings remain timely.
Frequently Asked Questions About the Philips CPAP Lawsuit in 2026
FAQ 1: Is the Philips CPAP lawsuit settlement still paying out in 2026?
Yes. The $1.1 billion personal injury and wrongful death settlement — reached in April and May of 2024 and covering claimants who registered by January 31, 2025 — is in active disbursement as of 2026. Payments are being distributed through a points-based allocation system that weights compensation by injury severity, with estimated individual payouts ranging from $100,000 to $500,000. However, disbursement does not mean all claims are resolved: 623 cases remain pending in MDL 3014 as of July 2026, and no court-approved individual cancer injury settlement offers have been issued in those outstanding cases.
FAQ 2: What cancers are linked to Philips CPAP foam exposure?
The primary cancers alleged in the Philips CPAP lawsuit involve the respiratory tract and upper airway, reflecting the route of exposure — direct inhalation of degraded foam particles and carcinogenic off-gases through the device’s breathing circuit. Lung cancer and nasal cancer are the core diagnoses driving personal injury claims. Serious inflammatory respiratory diseases — chronic airway inflammation, reactive airway dysfunction — are also included as qualifying injuries in the settlement framework. The chemicals identified in the foam degradation, including toluene diamine and toluene diisocyanate, are recognized as carcinogens or potential carcinogens in occupational health and toxicology literature, lending scientific support to the causal link alleged by plaintiffs.
FAQ 3: What is the August 2024 second Philips recall and who does it affect?
On August 4, 2024, the FDA issued a second, entirely separate Class I recall covering specific Philips BiPAP and ventilator models: the BiPAP A30, BiPAP A40, and V30 Auto ventilators. This recall was triggered not by foam chemical exposure but by a Ventilator Inoperative alarm failure — a defect causing the device’s emergency alarm system to malfunction or fail to activate when the ventilator stops working. The FDA confirmed at least 8 deaths and 13 injuries directly linked to this alarm failure. This recall creates a distinct category of potential claimants entirely separate from the 2021 foam recall litigation. Patients who relied on these ventilator models, particularly those with life-sustaining ventilator dependence, and families of those who died from undisclosed device failure, may have independent legal claims with statute of limitations periods running from 2024 and 2025.
FAQ 4: I missed the January 2025 settlement registration deadline. Do I have any legal options?
Missing the January 31, 2025 registration deadline for the $1.075 billion personal injury pool is a significant procedural obstacle for claimants seeking compensation under that specific settlement framework. However, several potential legal pathways may remain open depending on your specific circumstances. If you were harmed by the August 2024 second recall (the alarm failure in BiPAP A30/A40/V30 ventilators), that is a separate claim not governed by the 2021 recall settlement deadline. If you received a cancer diagnosis after the deadline and can argue under your state’s discovery rule that you could not reasonably have known of the causal link before registration closed, legal consultation is warranted. State statutes of limitations typically run 2 to 4 years from injury discovery, not from recall announcement. Individuals in this situation should consult a licensed attorney in their state as soon as possible given the time-sensitive nature of limitations periods.
FAQ 5: How much is a Philips CPAP personal injury claim worth?
Under the $1.1 billion settlement’s points-based allocation system, estimated individual settlement values for the Philips CPAP lawsuit range from approximately $100,000 to $500,000 per claim, with the exact amount determined by the severity and type of injury documented by each claimant. Cancer diagnoses — particularly lung and nasal cancers — receive higher point allocations than non-malignant respiratory injuries, reflecting the greater severity and life impact of those conditions. Wrongful death claims are also weighted accordingly. For the 623 cases still in active MDL litigation with no court-approved settlement offers as of July 2026, individual trial verdicts or future negotiated resolutions could yield values outside this range, either higher or lower, depending on the specific facts of each case, the strength of causation evidence, and whether punitive damages are pursued based on Philips’ internal knowledge timeline.
This article is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction for advice specific to your situation.
Related reading: Police Pursuit Negligence Damages: How Municipal Liability Grows When High-Speed Chases Injure Innocent Bystanders—$22M Chicago Settlement
Related reading: $10 Million Settlement: How Wrongful Death Damages Are Calculated When The Defendant Is A Police Department
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.